Christopher G. Chorley

Statistics

Publications

Citations

863

H-Index

Active since

2013

Affiliations

AstraZeneca (United Kingdom)(Current)

Christopher G. Chorley is an author at AstraZeneca (United Kingdom) specializing in drug discovery, tyrosine kinase inhibitors, and epidermal growth factor receptor inhibition.

Publications per year

2013–2014

Publications

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2013 · 261 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

1–2 of 2